PTC Therapeutics reported third-quarter 2026 total revenue of $358 million, up from $211.0 million a year earlier, and raised its full-year 2026 total and product revenue guidance. The company also recorded a net loss of $51.7 million, compared with net income of $15.9 million in the prior-year quarter, after a $111.0 million acquired in-process R&D charge for the ST-920 Fabry gene therapy.
Q3 2026 total revenue was $357.8 million, versus $211.0 million in Q3 2025; Sephience net product revenue was $181.9 million.
Net loss was $51.7 million ($0.62 per share) versus net income of $15.9 million a year earlier, including the $111.0 million ST-920 charge.
Full-year 2026 product revenue guidance was raised to $960 to $990 million from $850 to $950 million; total revenue guidance is $1.29 to $1.32 billion.
Cash, cash equivalents and marketable securities were $2,127.9 million on September 30, 2026.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
From PTC Therapeutics, Inc.'s 10-Q and 10-K filings (SEC XBRL). YoY compares each quarter with the same quarter a year earlier; it is blank when the year-ago figure is missing or negative.
Annual results
Fiscal year
Revenue
Growth
EPS (diluted)
Growth
Net margin
FY2025
$1.73B
+114.5%
$7.78
—
39.4%
FY2024
$806.78M
-14.0%
$-4.73
—
-45.0%
FY2023
$937.82M
+34.2%
$-8.37
—
-66.8%
FY2022
$698.80M
+29.7%
$-7.79
—
-80.0%
FY2021
$538.59M
+41.4%
$-7.43
—
-97.3%
Frequently asked questions
When is PTC Therapeutics's next earnings date?
PTC Therapeutics has not announced a report date within the next three weeks. US companies usually report three to six weeks after each quarter ends; this page updates as soon as the date is on the calendar.
What did PTC Therapeutics earn last quarter?
For the quarter ended Sep 2026, PTC Therapeutics reported diluted EPS of $-0.62 (-410.0% year over year) on revenue of $357.81M (+69.6%).
Where do these numbers come from?
Reported revenue, net income and EPS come from the company's own 10-Q and 10-K filings with the SEC (XBRL data). The report date and consensus estimate come from the Nasdaq earnings calendar.
Not investment advice. Figures can be restated by the company in later filings.